News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (308 of 354). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 354). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (35 of 354). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 266 of 354 items have one.
Landmarks worldwide to light up teal today for Alzheimer’s awareness
Today, landmarks around the world will be lit up teal as advocates globally work to raise awareness — throughout this entire month — about Alzheimer’s disease. …
Read at Alzheimer's News Today →Trial testing cholesterol-lowering med as potential Alzheimer’s intervention
NewAmsterdam Pharma has dosed the first participant in a large mid-stage clinical trial assessing the safety and effectiveness of its cholesterol-lowering treatment candidate obicetrapib as a potential aid for people with preclinical Alzheimer’s disease. …
Read at Alzheimer's News Today →At-home injection version of Alzheimer’s drug now available in US
In the U.S., people with early Alzheimer’s disease will now have the option for at-home treatment with the approved therapy Leqembi (lecanemab) throughout the entire treatment journey. …
Read at Alzheimer's News Today → Archived copy (2 Oct 2026), Internet ArchiveFDA designation may speed new treatment for Alzheimer’s psychosis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to remlifanserin, an experimental treatment that Acadia Pharmaceuticals is developing for hallucinations and delusions associated with Alzheimer’s disease psychosis. …
Read at Alzheimer's News Today →Study reports Alzheimer’s treatment gains in long-term care
Top-line data from a real-world study suggest that Zunveyl (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily functioning, and overall treatment experience in people with mild-to-moderate Alzheimer’s disease. …
Read at Alzheimer's News Today → Archived copy (12 Jul 2026), Internet ArchiveAwareness month event has new name: Do What You Love to End Alzheimer’s
June is Alzheimer’s & Brain Awareness Month, and the Alzheimer’s Association is holding a wide range of events to raise funds to fuel research and promote awareness of Alzheimer’s disease and other forms of dementia. …
Read at Alzheimer's News Today →FDA approves Auvelity to treat Alzheimer’s-related agitation
The U.S. Food and Drug Administration (FDA) has approved a new first-in-class treatment, Auvelity (dextromethorphan-bupropion), for the treatment of agitation associated with Alzheimer’s disease. …
Read at Alzheimer's News Today →Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
The benefits seen in people with early Alzheimer’s disease after a year of treatment with blarcamesine (Anavex 2-73) were sustained over nearly three years, according to new analysis from the treatment’s developer, Anavex Life Sciences. …
Read at Alzheimer's News Today → Archived copy (1 Jul 2026), Internet ArchiveResearchers explore surgical treatment’s potential in Alzheimer’s
Researchers are calling for more studies to determine whether lymphovenous anastomosis (LVA), a surgical procedure that helps clear molecular waste from the brain, might benefit people with Alzheimer’s disease. …
Read at Alzheimer's News Today → Archived copy (1 Jul 2026), Internet ArchiveFDA fast-tracks expanded home injections for Alzheimer’s drug Leqembi
The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an approved treatment for early Alzheimer’s disease. …
Read at Alzheimer's News Today →FDA decision on AXS-05 for Alzheimer’s agitation expected April 30
The U.S. Food and Drug Administration (FDA) granted priority review to an application from Axsome Therapeutics seeking approval of its oral therapy AXS-05 to treat agitation related to Alzheimer’s disease, and expects to decide by April 30, the company said. …
Read at Alzheimer's News Today → Archived copy (1 Jul 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.